Slide 1: Improved cash flow and solid performance in Europe
Improved cash flow and solid performance in Europe Q1 report 2025/26 Jonas Bolander, President and CEO Tobias Hägglöv, CFO Aug 28, 2025
Slide 2: Important information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future event
Slide 3: Business overview
Business overview Jonas Bolander President and CEO
Slide 4: Q1 – key takeaways
Q1 – key takeaways Improved cash flow and solid performance in Europe 1.05 Above 1, reflecting a healthy business environment Book-to-bill ratio 3%1 Continued strong momentum in Europe supported by new product launches Net sales growth 37.0% Lower GM YoY – FX and tariffs with an impact of 190 bps Ad
Slide 5: Q1 – Sales development by region
Q1 – Sales development by region Americas – decrease of -4%1 • Lower sales in U.S. mainly driven by customers awaiting Elekta Evo FDA EMEA clearance • Stable development in Latin America Americas 29% APAC – decrease of -4%1 (32%) 40% • Lower volumes in China and India Share (35%) APAC • Chinese sale
Slide 6: Commercial milestones during the first quarter
Commercial milestones during the first quarter ➢ Elekta Unity’s capability to treat prostate cancer Unity while preserving erectile function gained significant attention. University of ➢ Concluded a comprehensive deal including some Texas of our most advanced solutions to the University Southwestern
Slide 7: The most comprehensive product portfolio in the industry
The most comprehensive product portfolio in the industry – image guided and adaptive across the portfolio Neuro & Brachytherapy Linac solutions ONE Software suite Launches Several important commercial wins with Elekta Evo and our software suite Elekta ONE
Slide 8: Tariff situation – we are actively managing tariff cost increases in various ways
Tariff situation – we are actively managing tariff cost increases in various ways • U.S. localized software & service • China highly localized • Limited trade China – U.S. U.S. market 21%1 of Elekta sales Software Production in Europe – Linacs in UK, Brachy in the Netherlands and Neuro in Sweden 90
Slide 9: Financial overview
Financial overview Tobias Hägglöv CFO
Slide 10: Financial update Q1 25/26
Financial update Q1 25/26 (SEK M) Net sales increased by 3%1 Q1 25/26 Q1 24/25 Q4 24/25 • Continued strong momentum in Europe supported by product launches Net sales 3,646 3,825 5,156 • Solutions increased by 1% and Service grew by 4% – supported by Solutions 1,805 1,915 3,186 software growth Servic
Slide 11: EBIT margin – negative impact from net R&D partially offset by lower selling and admin expenses
EBIT margin – negative impact from net R&D partially offset by lower selling and admin expenses Adjusted EBIT bridge Q1 24/25 – Q1 25/26, reported Adj EBIT margin 7.4% 6.5% Gross profit 283 • Gross margin decline to 37% (37.8) with pressure from FX (-100 bps) and tariff costs (-90 bps). 235 • Price
Slide 12: Negative FX impact on the P&L
Negative FX impact on the P&L Q1 25/26 Operations FX Q1 24/25 Net sales 3,646 101 -279 3,825 • Negative FX impact on net sales driven by Growth, % -4.7% 2.6% -7.3% - stronger SEK vs main revenue currencies USD Adj. gross income 1,350 48 -143 1,445 and EUR Adj. gross margin 37.0% 37.8% Margin impact,
Slide 13: Improved cash flow year-over-year driven by working capital
Improved cash flow year-over-year driven by working capital Cash flow after continuous investments Q1 24/25 – Q1 25/26, SEK M -891 • Improved cash flow after continuous 122 -249 investments by SEK 529 M YoY -361 • Positive development driven by improved 647 working capital, particular receivables •
Slide 14: Key financial trends
Key financial trends Rolling twelve months, SEK M 0,042 21.000 18.117 17.725 17.883 18.016 17.838 0,040 18.000 37,8% 37,6% 15.000 0,038 36,7% 36,7% 36,7% 12.000 0,036 1.586 9.000 0,034 1.056 6.000 824 0,032 11,0% 10,6% 10,7% 11,6% 11,5% 582 681 3.000 0,030 0 Q1 24/25 Q2 24/25 Q3 24/25 Q4 24/25 Q1 25
Slide 15: Outlook
Outlook Jonas Bolander President and CEO
Slide 16: Outlook
Outlook Net sales is expected to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake Q2 25/26 in China. However, sales in China is expected to start to recover during the second half of 2025/26. Furthermore, a continuous negative i
Slide 17: Summary
Summary Jonas Bolander President and CEO
Slide 18: Summary
Summary • Solid performance in Europe supported by product launches • Lower GM YoY – FX and tariffs • Price improvements – price increases and product/market mix • Cash flow after continuous investments improved YoY by SEK 529 M
Slide 19: Financial calendar
Financial calendar Annual General Meeting 2025 Sep 4, 2025 Interim report, Q2 Aug-Oct 2025/26 Nov 26, 2025 Interim report, Q3 Nov-Jan 2025/26 Mar 5, 2026 Interim report, Q4 Feb-Apr 2025/26 May 28, 2026 Further questions Tobias Hägglöv Peter Nyquist CFO Head of Investor Relations +46 76 107 4799 +46
Slide 20: Q&A
Q&A
Slide 21: We don’t just build technology, we build hope
We don’t just build technology, we build hope
Slide 22: C©Elekta
C©Elekta